On Thursday, FDA issued an interim final rule requiring drug companies that are the sole manufacturers of certain critical medicines to report a potential shortage to federal officials. Previously, companies were required only to report permanent disruptions to drug supplies. However, the new rule states that "[s]ubsequent experience has showed that even temporary discontinuance of manufacturing can have a significant impact on patient access to drug products."